Study record · BPC-157
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
No measurable adverse changes were reported in the small acute observation window.
Key result
No measurable adverse changes were reported in the small acute observation window.
Study details
Study designPilot human exposure study
PhasePilot
PopulationTwo previously exposed adult participants
Sample size2
RouteIntravenous
Regimen / exposure10 mg on day 1; 20 mg on day 2
Duration2 days acute exposure
ComparatorNo placebo
Primary endpoint / questionAcute safety/biomarker observations
Safety resultNo acute safety signal detected in two people.
Key limitationsN=2, prior exposure, no control group, extremely short follow-up; cannot establish efficacy or general safety.
Registry / identifierPMID 40131143